Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Molecular Health launches Version 3.0 of software solution for precision medicine

MDBR Staff Writer Published 04 June 2018

Molecular Health has introduced Version 3.0 of Molecular Health Guide (MH Guide) software solution, offering enhanced support for precision medicine.

MH Guide, which is registered as an in vitro diagnostic device in the European Union, compares patient-specific molecular data with biomedical knowledge to provide an interactive, editable, medical report that supports treating physicians in assessing the range of therapy options identified for a patient's genomic profile.

Physicians are required to understand and interpret several biomarkers to evaluate their significance and make a reliable statement on the suitability of a specific cancer therapy.

MH Guide helps in finding clinically significant variants from entire exome analyses and will offer physician-approved variant interpretations that describe their clinical significance with reference to the patient’s disease.

Physicians can use this knowledge on each variant and follow references to the peer-reviewed sources as a basis for their clinical reports.

Molecular Health claims that the new Version 3.0 has an improved Association for Molecular Pathology (AMP) guideline-compliant biomarker classification scheme and supports Human Genome Variation Society (HGVS) variant nomenclature. 

MH Guide 3.0 users can now incorporate results from other important diagnostic tests in their reports, including protein expression, mutational burden, and microsatellite instability.

Customizable gene filters can let physicians to streamline workflow to focus on standard panels for genes of interest.

Along with physician-approved variant interpretations, there are variant details from available from standard sources recommended by variant classification guidelines. These support physicians in assessing clinical significant of a variant.

Molecular Health chief information officer Rudolf Caspary said: "MH Guide 3.0 marks a further milestone in cancer treatment based on the genetic variants in a tumor. It gives the treating oncologist a fast and comprehensive overview of treatment recommendations.

"We can help to significantly facilitate and improve the daily clinical routine of the treating physicians, while delivering well-informed therapy decisions. Ultimately, this benefits patients - and the entire healthcare system."